News
-
Jan 22, 2025
C3i Announces the Promotion of Jamie Sharp to Associate Director of Business Development
Read MoreC3i is pleased to announce Jamie Sharp’s promotion to Associate Director of Business Development. This milestone marks a key step in our growth strategy and reflects Jamie’s significant impact on our company’s development. Jamie Sharp is a biotechnology and cell and gene therapy specialist for CDMOs. Holding a Ph.D. with a background in chemical engineering […]
-
Oct 21, 2024
C3i appoints Yvan Côté as Chief Executive Officer, Paving the way for Strategic Growth and Innovation.
Read MoreThis fall has brought a new dynamic to C3i with the appointment of our new CEO, Yvan Côté. His expertise and leadership reinforce our commitment to elevating C3i to new heights. With a background in biotechnology and cell biology, combined with his strong business development expertise, Yvan has played a pivotal role in the significant […]
-
Jun 20, 2024
C3i Center Inc is the First CDMO in Canada to Receive Approval for a Drug Establishment License to Commercially Produce Cell Therapy Drug Products.
Read MoreWe are very proud to announce that we have received regulatory approval, in the form of a Drug Establishment License (DEL), to commercially produce cell therapies. This makes us the first CDMO in Canada to achieve this milestone. The approval follows an inspection by the cell and gene therapy experts from Health Canada. The DEL […]
-
Feb 26, 2024
With the Support of NGen, C3i is Partnering up for Advanced Biomanufacturing of Cartilage Implants Using Cocoon Automation.
Read MoreC3i is pleased to partner with Octane Orthobiologics Inc and Orthopaedic Innovation Center Inc with the support of NGen for automation and scale up the biomanufacturing of cartilage implants for commercial-level production. NGen has announced over $32.3 million in Global Innovation Cluster funding for 15 new advanced manufacturing projects. With industry contributions of $54.4 million, […]
-
Sep 20, 2023
CDMO C3i Center Inc Located in Montreal, Canada Has Begun Manufacturing a Cell Therapy Product for Europe.
Read MoreThe Montreal-based CDMO C3i Center Inc is paving the way in the cell and gene therapy industry in North American and Canada as one of a few contract development and manufacturing organizations (CDMOs) to be producing in North America and for Europe. “We are proud of our team has worked very hard to be able […]
-
Aug 07, 2023
C3i is proud to sponsor Meeting on the MESA 23, North America’s leading gathering of experts and leaders in the cell and gene therapy sector.
Read MoreC3i is a platinum sponsor for the Alliance for Regenerative Medicine’s 2023 Cell and Gene Meeting on the Mesa from October 10 – 12, 2023. We look forward to connecting with senior executives and top stakeholders to tackle the most pressing issues in cell and gene therapies. To learn more about this event: https://meetingonthemesa.com/ See […]
-
Jan 10, 2022
C3i Profiled in Outsourced Pharma
Read MoreC3i CEO Louisa Petropoulos was recently featured in Outsourced Pharma online, discussing the present and future prospects of contract research organizations and Canadian innovation, as well as C3i’s accomplishments upon its 5th anniversary. Click here to read the story.
-
Dec 16, 2021
AstraZeneca supports the growth of the C3i Lymphoma Registry, a project lead by Dr. Isabelle Fleury at Hôpital Maisonneuve-Rosemont
Read MoreThe C3i Center (C3i) is proud to announce the participation of AstraZeneca Canada (AstraZeneca) in supporting the development of the Lymphoma Registry. This state of the art registry, launched in September 2017 under the leadership of Dr. Isabelle Fleury, hematologist and medical oncologist at Institut universitaire d’hématologie-oncologie-thérapie cellulaire (IUHOTC) at Centre intégré universitaire de santé […]
-
Nov 04, 2021
C3i Center Inc. Secures CAP Accreditation, Launches New Lab Spinoff
Read MoreC3i Center Inc. has strengthened our position as Canada’s leading one-stop contract development and manufacturing organization operating in the cell therapy space with two important developments.